Leerink Partnrs Comments on CNTA Q1 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Centessa Pharmaceuticals in a research note issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

A number of other equities analysts have also recently weighed in on the company. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday. Finally, Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Trading Down 0.2 %

CNTA stock opened at $14.51 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The company’s 50-day simple moving average is $16.49 and its 200-day simple moving average is $16.41. The firm has a market cap of $1.91 billion, a P/E ratio of -9.48 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CNTA. Geode Capital Management LLC lifted its position in Centessa Pharmaceuticals by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after buying an additional 660 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth $31,000. Barclays PLC raised its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 260,168 shares of company stock worth $4,309,568 over the last quarter. 11.59% of the stock is currently owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.